bacitracin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	281	1405-87-4

Description:

Molecule	Description
Synonyms: bacitracin baciguent bacillichin bacilliquin bacitracin zinc bacitracin methylene disalicylate	A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140) Molecular weight: 5648.77 Formula: C261H406N68O64S4 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 530.87 ALOGS: ROTB: None

Molecule

Description

Synonyms:

bacitracin
baciguent
bacillichin
bacilliquin
bacitracin zinc
bacitracin methylene disalicylate

A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140)

Molecular weight: 5648.77
Formula: C261H406N68O64S4
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 530.87
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 29, 1948	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	392.50	18.28	216	2698	310471	63175637
Lymphatic disorder	29.05	18.28	6	2908	375	63485733

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	45.19	20.33	41	2480	80488	34873922
Renal injury	21.22	20.33	12	2509	11183	34943227

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	201.47	16.44	155	4553	298761	79440919
Lymphatic disorder	28.23	16.44	6	4702	334	79739346
Renal injury	23.97	16.44	14	4694	16913	79722767
Unevaluable event	23.18	16.44	22	4686	55563	79684117
Slow response to stimuli	22.33	16.44	7	4701	1818	79737862
Anaphylactic reaction	22.15	16.44	26	4682	83717	79655963
Mental status changes	21.49	16.44	23	4685	66936	79672744
Tachypnoea	17.96	16.44	15	4693	32048	79707632

Showing 1 to 8 of 8 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	D06AX05	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use
ATC	J01XX10	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Other antibacterials
ATC	R02AB04	RESPIRATORY SYSTEM THROAT PREPARATIONS THROAT PREPARATIONS Antibiotics
CHEBI has role	CHEBI:33282	bactericides
CHEBI has role	CHEBI:176497	geroprotectors
FDA PE	N0000008479	Decreased Cell Wall Synthesis & Repair
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Keratitis	indication	5888003	DOID:4677
Blepharoconjunctivitis	indication	68659002	DOID:2456
Corneal abrasion	indication	85848002
Infective blepharitis	indication	312219000
Bacterial keratitis	indication	314557000
Superficial Ocular Infection	indication
Minor Bacterial Skin Infections	indication
Dacryocystitis	off-label use	85777005	DOID:9938
Corneal ulcer	off-label use	91514001	DOID:8463
Bacterial conjunctivitis	off-label use	128350005	DOID:9700

Showing 1 to 10 of 42 entries

Previous1 2 3 4 5Next

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Cattle	Necrotic enteritis caused or complicated by Clostridium species	Indication
Cattle	To increase rate of weight gain	Indication
Cattle	To improve feed efficiency	Indication
Cattle	To increases egg production	Indication
Chickens	Necrotic enteritis caused or complicated by Clostridium species	Indication
Chickens	To increase rate of weight gain	Indication
Chickens	Improves feed efficiency during the first seven months of production	Indication
Chickens	Increases egg productionduring the first seven months of production	Indication
Pheasants	To increase rate of weight gain	Indication
Pheasants	To improve feed efficiency	Indication

Showing 1 to 10 of 19 entries

Previous1 2Next

🐶 Veterinary products

Show entries

Search:

Product	Applicant	Ingredients
Albac / Amprol Hi-E	Zoetis Inc.	3
Albac / Bio-Cox	Zoetis Inc.	2
Albac / Coban	Zoetis Inc.	2
Albac / Coyden 25	Zoetis Inc.	2
Albac / Deccox	Zoetis Inc.	2
Albac / Deccox, Broiler Finisher Medicated	Zoetis Inc.	2
Albac / Robenz	Zoetis Inc.	2
Albac / Sacox	Zoetis Inc.	2
Albac 50 plus Nicarb	Zoetis Inc.	2
Albac 50 Type A Medicated Article	Zoetis Inc.	1

Showing 1 to 10 of 71 entries

Previous1 2 3 4 5…8Next

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	IC50	5.27	DRUG MATRIX
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN	IC50	5.72	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT	Ki	5.87	DRUG MATRIX
Undecaprenyl-diphosphatase	Unclassified		UPPP_ECOLI	IC50	5.25	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
002798	NDDF
002799	NDDF
10909430	PUBCHEM_CID
11417	RXNORM
1167	INN_ID
1405-89-6	SECONDARY_CAS_RN
31707003	SNOMEDCT_US
370330005	SNOMEDCT_US
4017493	VUID
4017493	VANDF

Showing 1 to 10 of 30 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AntibioticMaximum Strength	HUMAN OTC DRUG LABEL	3	0363-0018	OINTMENT	500 [iU]	TOPICAL	OTC monograph final	13 sections
AntibioticMaximum Strength	HUMAN OTC DRUG LABEL	3	0363-0018	OINTMENT	500 [iU]	TOPICAL	OTC monograph final	13 sections
Bacitracin	HUMAN OTC DRUG LABEL	1	0363-0075	OINTMENT	500 [USPU]	TOPICAL	OTC monograph final	14 sections
Bacitracin Zinc	HUMAN OTC DRUG LABEL	1	0404-0170	OINTMENT	500 [iU]	TOPICAL	OTC monograph final	14 sections
Bacitracin Zinc	HUMAN OTC DRUG LABEL	1	0404-0172	OINTMENT	500 [iU]	TOPICAL	OTC monograph final	14 sections
Bacitracin Zinc and Polymyxin B Sulfate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0273	OINTMENT	500 1	OPHTHALMIC	ANDA	17 sections
Bacitracin Zinc, Neomycin Sulfate, and Polymyxin B Sulfate	HUMAN OTC DRUG LABEL	3	0404-0167	OINTMENT	400 [iU]	TOPICAL	OTC monograph final	12 sections
Bacitracin Zinc, Polymyxin B Sulfate, and Neomycin Sulfate	HUMAN OTC DRUG LABEL	3	0404-0171	OINTMENT	400 [iU]	TOPICAL	OTC monograph final	12 sections
basic care first aid antibiotic	HUMAN OTC DRUG LABEL	3	0113-0701	OINTMENT	400 [USPU]	TOPICAL	OTC monograph final	13 sections
Basic Care First Aid Antibiotic Plus Pain Relief	HUMAN OTC DRUG LABEL	4	0113-7679	OINTMENT	500 [USPU]	TOPICAL	OTC monograph final	13 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next